Modern Treatment of Rectal Cancer Closes the Gap Between Common Adenocarcinoma and Mucinous Carcinoma

Niek Hugen*, Cornelis J. van de Velde, Steven L. Bosch, Jurgen J. Futterer, Marloes A. Elferink, Corrie A. Marijnen, Harm J. Rutten, Johannes H. de Wilt, Iris D. Nagtegaal

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Mucinous carcinoma (MC) is a distinct form of rectal cancer (RC) comprising 10?% of all cases and has been associated with an impaired prognosis compared with non-mucinous adenocarcinoma (AC). The benefit of today's modern treatment for MC patients is unknown but a prospective randomized trial to answer this does not seem feasible. This study provides an analysis of the modern treatment of rectal MC and efficacy of preoperative therapies for MC patients.Data from three large (trial) cohorts were used. Data from the Netherlands Cancer Registry (NCR) were used to analyze the prognosis of RC patients over time (N?=?38,035). To study the benefit of preoperative short-term radiotherapy, patients from the total mesorectal excision (TME) trial (N?=?1,530) were selected, and the benefit from preoperative chemoradiotherapy was analyzed with data on 540 locally advanced RC (LARC) patients from two hospitals.Data from the NCR confirmed that 5-year overall survival for MC was significantly worse from 1989 to 1998, but no longer different from AC from 1999 onwards. MC patients had a higher rate of positive circumferential resection margin than AC patients (TME trial 27.2 vs. 16.5?%, p?=?0.006; LARC cohort 34.5 vs. 9.8?%, p?
Original languageEnglish
Pages (from-to)2669-2676
JournalAnnals of Surgical Oncology
Issue number8
Publication statusPublished - Aug 2015

Cite this